- Home
- APLM vs KXIN Comparison
APLM vs KXIN Comparison
Compare APLM & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- KXIN
- Stock Information
- Founded
- APLM 2016
- KXIN 2015
- Country
- APLM United States
- KXIN China
- Employees
- APLM N/A
- KXIN N/A
- Industry
- APLM Blank Checks
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- APLM Finance
- KXIN Consumer Discretionary
- Exchange
- APLM Nasdaq
- KXIN Nasdaq
- Market Cap
- APLM 7.7M
- KXIN 9.0M
- IPO Year
- APLM N/A
- KXIN N/A
- Fundamental
- Price
- APLM $6.51
- KXIN $1.00
- Analyst Decision
- APLM Strong Buy
- KXIN
- Analyst Count
- APLM 1
- KXIN 0
- Target Price
- APLM $200.00
- KXIN N/A
- AVG Volume (30 Days)
- APLM 57.8K
- KXIN 105.3K
- Earning Date
- APLM 04-03-2025
- KXIN 11-26-2019
- Dividend Yield
- APLM N/A
- KXIN N/A
- EPS Growth
- APLM N/A
- KXIN N/A
- EPS
- APLM N/A
- KXIN N/A
- Revenue
- APLM $198,000.00
- KXIN N/A
- Revenue This Year
- APLM $415.15
- KXIN N/A
- Revenue Next Year
- APLM N/A
- KXIN N/A
- P/E Ratio
- APLM N/A
- KXIN N/A
- Revenue Growth
- APLM N/A
- KXIN N/A
- 52 Week Low
- APLM $4.71
- KXIN $0.64
- 52 Week High
- APLM $53.00
- KXIN $29.52
- Technical
- Relative Strength Index (RSI)
- APLM 49.37
- KXIN 49.99
- Support Level
- APLM $5.41
- KXIN $0.88
- Resistance Level
- APLM $6.19
- KXIN $1.20
- Average True Range (ATR)
- APLM 0.77
- KXIN 0.12
- MACD
- APLM 0.08
- KXIN 0.02
- Stochastic Oscillator
- APLM 95.24
- KXIN 64.54
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.